Literature DB >> 17325866

Secondary acute promyelocytic leukemia: an increasingly common entity.

E Jantunen, K Heinonen, E Mahlamäki, K Penttilä, T Kuittinen, P Lehtonen, M Pyörälä, A Hänninen, T Nousiainen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17325866     DOI： 10.1080/10428190600961736

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  4 in total

Review 1.  Global characteristics of childhood acute promyelocytic leukemia.

Authors:  L Zhang; A Samad; M S Pombo-de-Oliveira; G Scelo; M T Smith; J Feusner; J L Wiemels; C Metayer
Journal:  Blood Rev       Date:  2014-09-30       Impact factor: 8.250

2.  Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Authors:  S Kayser; J Krzykalla; M A Elliott; K Norsworthy; P Gonzales; R K Hills; M R Baer; Z Ráčil; J Mayer; J Novak; P Žák; T Szotkowski; D Grimwade; N H Russell; R B Walter; E H Estey; J Westermann; M Görner; A Benner; A Krämer; B D Smith; A K Burnett; C Thiede; C Röllig; A D Ho; G Ehninger; R F Schlenk; M S Tallman; M J Levis; U Platzbecker
Journal:  Leukemia       Date:  2017-03-21       Impact factor: 11.528

3.  Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.

Authors:  Farshid Dayyani; Hagop Kantarjian; Susan O'Brien; Sherry Pierce; Dan Jones; Stefan Faderl; Guillermo Garcia-Manero; Jorge Cortes; Farhad Ravandi
Journal:  Cancer       Date:  2010-08-27       Impact factor: 6.860

4.  Prognosis and therapy when acute promyelocytic leukemia and other "good risk" acute myeloid leukemias occur as a therapy-related myeloid neoplasm.

Authors:  Richard A Larson; Michelle M Le Beau
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-07-08       Impact factor: 2.576
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.